Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2017, Article ID 2842935, 3 pages
Case Report

Development of New Deep Venous Thrombosis While on Apixaban

1Department of Internal Medicine, Easton Hospital, Easton, PA, USA
2Drexel University College of Medicine, Electrophysiology Department, Easton Hospital, Easton, PA, USA

Correspondence should be addressed to Munish Sharma; moc.liamg@demtnihsinum

Received 24 April 2017; Revised 17 May 2017; Accepted 29 May 2017; Published 20 June 2017

Academic Editor: Konstantinos P. Letsas

Copyright © 2017 Munish Sharma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment option in comparison to warfarin. However, cases of treatment failure mainly due to interindividual variation in plasma drug levels can be seen rarely. In this report we describe a case of acute DVT of right lower extremity in a patient who was on apixaban for prevention of venous thromboembolism (VTE) due to underlying nonvalvular atrial fibrillation (NVAF).